Changes (01/05/2017) Ovarian Epithelial, FT, PP Cancer (NCI)

National Cancer Institute
 Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version

Go to Patient Version

 

Sections

• General Information About Ovarian Epithelial Cancer, Fallopian Tube Cancer (FTC), and Primary Peritoneal Cancer (PPC)
• Cellular Classification of Ovarian Epithelial Cancer, FTC, and PPC
• Stage Information for Ovarian Epithelial Cancer, FTC, and PPC
• Treatment Option Overview
• Early-Stage Ovarian Epithelial Cancer, FTC, and PPC Treatment
• Advanced-Stage Ovarian Epithelial Cancer, FTC, and PPC Treatment
• Recurrent or Persistent Ovarian Epithelial Cancer, FTC, and PPC Treatment
• Changes to This Summary (01/​05/​2017)
• About This PDQ Summary
• View All Sections

Changes to This Summary (01/05/2017)

Advanced-Stage Ovarian Epithelial Cancer, Fallopian Tube Cancer (FTC), and Primary Peritoneal Cancer (PPC) Treatment

 

Revised a standard treatment option for advanced-stage ovarian epithelial cancer, FTC, and PPC to surgery followed by chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors.

The Surgery followed by chemotherapy and PARP inhibitors subsection was extensively revised.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.